{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:19:35Z","timestamp":1791332375093,"version":"4.3.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\/Objectives<\/jats:title>\n            <jats:p>This study aimed to evaluate the long-term (7 years) outcome of visual acuity in patients with neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor (VEGF) agents following the observe-and-plan regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Subjects\/Methods<\/jats:title>\n            <jats:p>A total of 195 eyes from 181 patients with nAMD (mean age 79.5\u2009\u00b1\u20096.9 years), with a mean follow-up duration of 66\u2009\u00b1\u200937 months, treated with intravitreal anti-VEGF (ranibizumab or aflibercept) were included in this retrospective study. The principles of the observe-and-plan regimen were followed, with follow-up exceeding 3 years in real-life settings. Data collected included visual acuity (VA), number of injections and visits, central retinal thickness, and any complications over 7 years from baseline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The mean baseline VA was 63\u2009\u00b1\u200917 Early Treatment of Diabetic Retinopathy Study letters (Snellen equivalent 20\/63), improving to 73\u2009\u00b1\u200914 at year 1. The initial visual gain was slightly reduced with a final mean VA of 70\u2009\u00b1\u200918 letters (Snellen equivalent 20\/40) at year 7. The mean central macular thickness decreased significantly from 375\u2009\u00b1\u2009129 at baseline to 276\u2009\u00b1\u200975 at year 1 and to 279\u2009\u00b1\u200987 at year 7. The mean annual number of injections decreased from 8.7\u2009\u00b1\u20093.2 in year 1 to 6.7\u2009\u00b1\u20093.7 in year 2 and to 5.5\u2009\u00b1\u20092.8 in year 7. The mean annual number of visits remained constant throughout, with 4.1\u2009\u00b1\u20091.3 visits in year 1 and 4.7\u2009\u00b1\u20091.7 in year 7.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The observe-and-plan regimen was very efficient for treating nAMD in real-life settings, reducing the clinical burden on the medical system and patients, with excellent functional and structural long-term results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41433-025-03830-1","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T11:40:43Z","timestamp":1746877243000},"page":"2188-2193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term outcomes of the observe-and-plan regimen in treating neovascular age-related macular degeneration: a retrospective real-life analysis"],"prefix":"10.1038","volume":"39","author":[{"given":"M.","family":"Sherif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Derradji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Safi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8822-8194","authenticated-orcid":false,"given":"I.","family":"Mantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"3830_CR1","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","volume":"358","author":"RD Jager","year":"2008","unstructured":"Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606\u201317.","journal-title":"N Engl J Med"},{"key":"3830_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","volume":"115","author":"TY Wong","year":"2008","unstructured":"Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116\u201326.","journal-title":"Ophthalmology"},{"key":"3830_CR3","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S0008-4182(05)80078-X","volume":"40","author":"EWM Ng","year":"2005","unstructured":"Ng EWM, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol. 2005;40:352\u201368.","journal-title":"Can J Ophthalmol"},{"key":"3830_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388\u201398.","journal-title":"Ophthalmology"},{"key":"3830_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432\u201344.","journal-title":"N Engl J Med"},{"key":"3830_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331.","journal-title":"N Engl J Med"},{"key":"3830_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF Trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537\u201348.","journal-title":"Ophthalmology"},{"key":"3830_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121:193\u2013201.","journal-title":"Ophthalmology"},{"key":"3830_CR9","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","volume":"120","author":"S Rofagha","year":"2013","unstructured":"Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in Anchor, Marina, and Horizon: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292\u20139.","journal-title":"Ophthalmology"},{"key":"3830_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","volume":"37","author":"D Rosenberg","year":"2023","unstructured":"Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, et al. Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye. 2023;37:6\u201316.","journal-title":"Eye"},{"key":"3830_CR11","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1097\/IAE.0b013e3181bfbd46","volume":"29","author":"M Engelbert","year":"2009","unstructured":"Engelbert M, Zweifel SA, Freund KB. Treat and extend\u201d dosing of intravitreal anti-vascular endothelial growth factor therapy for type 3 neovascularization\/retinal angiomatous proliferation. Retina. 2009;29:1424\u201331.","journal-title":"Retina"},{"key":"3830_CR12","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendations. Retina. 2015;35:1489\u2013506.","journal-title":"Retina"},{"key":"3830_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03937-7","volume":"21","author":"LM Khachigian","year":"2023","unstructured":"Khachigian LM, Liew G, Teo KYC, Wong TY, Mitchell P. Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration. J Transl Med. 2023;21:133.","journal-title":"J Transl Med"},{"key":"3830_CR14","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98:1144\u201367.","journal-title":"Br J Ophthalmol"},{"key":"3830_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/tvst.4.3.6","volume":"4","author":"I Mantel","year":"2015","unstructured":"Mantel I. Optimizing the anti-VEGF treatment strategy for neovascular age-related macular degeneration: from clinical trials to real-life requirements. Transl Vis Sci Technol. 2015;4:6.","journal-title":"Transl Vis Sci Technol"},{"key":"3830_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/eye.2014.321","volume":"29","author":"C Gianniou","year":"2015","unstructured":"Gianniou C, Dirani A, Ferrini W, Marchionno L, Decugis D, Deli A, et al. Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. Eye. 2015;29:450\u20131.","journal-title":"Eye"},{"key":"3830_CR17","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/bjophthalmol-2013-304556","volume":"98","author":"I Mantel","year":"2014","unstructured":"Mantel I, Niderprim SA, Gianniou C, Deli A, Ambresin A. Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. Br J Ophthalmol. 2014;98:1192\u20136.","journal-title":"Br J Ophthalmol"},{"key":"3830_CR18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00417-012-2090-9","volume":"251","author":"I Mantel","year":"2013","unstructured":"Mantel I, Deli A, Iglesias K, Ambresin A. Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2013;251:697\u2013704.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"3830_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of neovascular age-related macular degeneration after 10 years of anti-vascular endothelial growth factor therapy in the real world: the need for A change of mindset. Ophthalmologica. 2020;243:1\u20138.","journal-title":"Ophthalmologica"},{"key":"3830_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS, Williams DF. Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: A real-world analysis of 49485 eyes. Ophthalmol Retin. 2020;4:19\u201330.","journal-title":"Ophthalmol Retin"},{"key":"3830_CR21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","volume":"121","author":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group EMR Users Group","year":"2014","unstructured":"Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group EMR Users Group. \u2018The neovascular age-related macular degeneration database: multicenter study of 92\u2009976 ranibizumab injections: report 1: visual acuity: report 1. Ophthalmology. 2014;121:1092\u2013101.","journal-title":"Ophthalmology"},{"key":"3830_CR22","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1136\/bjophthalmol-2017-311055","volume":"102","author":"M Kataja","year":"2018","unstructured":"Kataja M, Hujanen P, Huhtala H, Kaarniranta K, Tuulonen A, Uusitalo-Jarvinen H. Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting. Br J Ophthalmol. 2018;102:959\u201365.","journal-title":"Br J Ophthalmol"},{"key":"3830_CR23","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, et al. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Ophthalmology. 2016;123:1751\u201361.","journal-title":"Ophthalmology"},{"key":"3830_CR24","doi-asserted-by":"crossref","unstructured":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, et al. Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials. Comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. 2016; 123:1751\u201361.","DOI":"10.1016\/j.ophtha.2016.03.045"},{"key":"3830_CR25","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","volume":"122","author":"MC Gillies","year":"2015","unstructured":"Gillies MC, Campain A, Barthelmes D, Simpson JM, Arnold JJ, Guymer RH, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology. 2015;122:1837\u201345.","journal-title":"Ophthalmology"},{"key":"3830_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.oret.2020.09.019","volume":"5","author":"K Spooner","year":"2021","unstructured":"Spooner K, Fraser-Bell S, Hong T, Phan L, Wong JG, Chang A. Long-term anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: the LATAR study: Report 1: Ten-Year, Real-World Outcomes: Report 1. Ophthalmol Retin. 2021;5:511\u20138.","journal-title":"Ophthalmol Retin"},{"key":"3830_CR27","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.oret.2020.05.005","volume":"4","author":"FF Kung","year":"2020","unstructured":"Kung FF, Starr MR, Bui YT, Mejia CA, Bakri SJ. Long-term follow-up of patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections. Ophthalmol Retin. 2020;4:1047\u201353.","journal-title":"Ophthalmol Retin"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03830-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03830-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:24:13Z","timestamp":1757168653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03830-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3830"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03830-1","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}